Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $139.96 USD
Change Today +1.30 / 0.94%
Volume 643.9K
TMO On Other Exchanges
New York
As of 5:15 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

thermo fisher scientific inc (TMO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/15 - $141.25
52 Week Low
09/28/15 - $117.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

thermo fisher scientific inc (TMO) Details

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables used in biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases. This segment serves pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for applications in the laboratory, on the production line, and in the field. It serves pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as the clinical laboratory. The company’s Specialty Diagnostics segment offers liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, and calibration verification fluids; blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; and human leukocyte antigen typing and testing for the organ transplant market. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratory customers. Its Laboratory Products and Services segment offers sample preparation and preservation equipment, cold storage equipment, centrifugation products, biological safety cabinets, temperature control products, water analysis instruments, and other laboratory equipment, as well as laboratory consumables, research and safety market solutions, and biopharma services. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

51,000 Employees
Last Reported Date: 03/5/15
Founded in 1956

thermo fisher scientific inc (TMO) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.3M
Executive Vice President and President of Lif...
Total Annual Compensation: $723.1K
Executive Vice President and President of Lab...
Total Annual Compensation: $716.2K
Senior Vice President and President of Analyt...
Total Annual Compensation: $568.1K
Chief Administrative Officer, Senior Vice Pre...
Total Annual Compensation: $674.0K
Compensation as of Fiscal Year 2014.

thermo fisher scientific inc (TMO) Key Developments

Alan Malus to Retire as Executive Vice President of Thermo Fisher Scientific Inc., Effective June 1, 2016

On November 17, 2015, Alan Malus, Executive Vice President of Thermo Fisher Scientific Inc. informed the company of his decision to retire effective June 1, 2016.

Thermo Fisher Scientific, Inc. Signs Development Agreement with Novartis and Pfizer for Sequencing-Based Companion Diagnostic

Thermo Fisher Scientific entered into a long-term agreement with Novartis and Pfizer to develop and commercialize a multi-marker, universal sequencing (NGS) oncology test that will serve as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC) across multiple drug development programs. The streamlined and personalized methodology defined in the development agreement between the companies has the potential to improve safety, effectiveness and health outcome of patients via targeted risk stratification and tailored treatment approaches. The collaboration, focused on a universal testing approach, could also accelerate the development and registration of several new NSCLC drugs and drug indications, with the ultimate goal of providing patients greater access to more targeted treatments and appropriate clinical trials as quickly as possible. The NGS-based companion diagnostic test for NSCLC will be developed using Thermo Fisher’s Ion PGM Dx System and Oncomine assays. Both the NGS platform and Oncomine reagents leverage the Ion AmpliSeq technology, which enables simultaneous sequencing of hundreds of genes, with high reproducibility and rapid turnaround time. Combined with its uniquely low DNA and RNA sample input requirements from Formalin-Fixed Paraffin-Embedded (FFPE) tissues (as little as 10ng extracted nucleic acid per reaction), the Ion Torrent-based sequencing platform and reagents offer comprehensive sequence analysis of a wider variety of tumor samples, including limited or compromised specimens derived from FFPE tissue or fine needle aspirates. Incorporating oncology markers relevant to a broad range of cancers, the NGS panel will also provide a universal platform to enable potential new clinical indications for existing drugs and development of possible new therapies for other indications in the future.

Thermo Fisher Mulls Acquisitions

Thermo Fisher Scientific, Inc. (NYSE:TMO) is seeking acquisitions. Thermo Fisher will use the remaining proceeds from the offering of senior notes for funding of possible acquisitions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TMO:US $139.96 USD +1.30

TMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.42 USD +0.01
Biogen Inc $293.21 USD +0.91
Danaher Corp $96.85 USD +0.02
Safran SA €68.89 EUR +0.03
Syngenta AG SFr.378.00 CHF +0.50
View Industry Companies

Industry Analysis


Industry Average

Valuation TMO Industry Range
Price/Earnings 28.5x
Price/Sales 3.3x
Price/Book 2.7x
Price/Cash Flow 28.3x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact THERMO FISHER SCIENTIFIC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at